Markus Zettl

Medicine · Health Sciences

19h-index1.8kcitations75works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(47), CAR-T cell therapy research(40), Radiopharmaceutical Chemistry and Applications(34), Cancer Immunotherapy and Biomarkers(12), HER2/EGFR in Cancer Research(10)

Publications75 total

Supplementary Table S5 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
2025Open Access
Supplementary Figure S1 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
2025Open Access
Supplementary Table S3 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
2025Open Access
Supplementary Table S2 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
2025Open Access
Supplementary Figure S2 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
2025Open Access
Supplementary Table S1 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
2025Open Access
Supplementary Table S4 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
2025Open Access
Data from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
2025Open Access
A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
Clinical Cancer Research·2024· 9 citedOpen Access
Supplementary Data from PD-1 and LAG-3 Dominate Checkpoint Receptor–Mediated T-cell Inhibition in Renal Cell Carcinoma
2023Open Access
Data from PD-1 and LAG-3 Dominate Checkpoint Receptor–Mediated T-cell Inhibition in Renal Cell Carcinoma
2023Open Access
Supplementary Data from PD-1 and LAG-3 Dominate Checkpoint Receptor–Mediated T-cell Inhibition in Renal Cell Carcinoma
2023Open Access
Data from PD-1 and LAG-3 Dominate Checkpoint Receptor–Mediated T-cell Inhibition in Renal Cell Carcinoma
2023Open Access
Supplementary Figure from The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner
2023Open Access
Supplementary Figure from The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner
2023Open Access
Supplementary Figure from The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner
2023Open Access
Supplementary Table from The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner
2023Open Access
Supplementary Table from The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner
2023Open Access
Supplementary Figure from The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner
2023Open Access
Supplementary Figure from The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Shane A. Olwill(27), Eva-Maria Hansbauer(24), Janet K. Peper-Gabriel(18), Marina Pavlidou(18), Lucia Pattarini(18), Aizea Morales‐Kastresana(18), Thomas J. Jaquin(18), Catherine Gallou(18), Marleen Richter(18), Hélène Lelièvre(18), Alix Scholer‐Dahirel(18), Birgit Bossenmaier(18), Celine Sancerne(18), Matthieu Rivière(18), Maximilien Grandclaudon(18), Rachida S. Bel Aiba(18), Christine Rothe(18), Véronique Blanc(18), Sarina A. Piha‐Paul(9), Sara A. Hurvitz(9)